Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Pediatric Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1641088

Expression of aberrant markers in monitoring of measurable residual disease in B-cell precursor acute lymphoblastic leukemia patients during remission-inducing therapy phase

Provisionally accepted
Łukasz SłotaŁukasz Słota1*Łukasz SędekŁukasz Sędek2Monika LejmanMonika Lejman3Bartosz PerkowskiBartosz Perkowski1Aleksandra LasiaAleksandra Lasia1Joanna BulsaJoanna Bulsa1Wojciech MlynarskiWojciech Mlynarski4Jerzy KowalczykJerzy Kowalczyk3Tomasz SzczepańskiTomasz Szczepański1
  • 1Medical University of Silesia in Katowice, Department of Pediatric, Hematology and Oncology in Zabrze, Katowice, Poland
  • 2Medical Univeristy of Silesia in Katowice, Department of Microbiology and Immunology in Zabrze, Poland, Katowice, Poland
  • 3Department of Pediatric, Hematology, Oncology and Transplantology, Medical University of Lublin, Poland, Lublin, Poland
  • 4Department of Pediatrics, Oncology and Hematology, Medical University of Łódź, Poland, Lodz, Poland

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

B-cell acute lymphoblastic leukemia (BCP-ALL) is characterized by an abnormal proliferation of immature cells in bone marrow. Leukemic blasts at diagnosis exhibit a so-called leukemia associated immunophenotype (LAIP), which is further used for determination of measurable residual disease (MRD) levels at particular time points during the therapy. Nevertheless, in some patients LAIP proves insufficient for discrimination of blasts from their normal counterparts, therefore, search for novel, aberrant markers is essential. A crucial requirement for these antigens is their expression variability throughout the entire treatment monitoring period.The aim of the study was to assess the expression level of four markers: CD66c, CD304, CD72 and CD86 on leukemic cells at diagnosis and at day 15 and 33 of treatment to compare stability of their expression. We also correlated the results obtained with the most common genetic aberrations

Keywords: Flow Cytometry, measurable residual disease, B-cell precursor acute lymphoblastic leukemia, Childhood acute leukemia, antigen expression hyper-hypodiploidy, BCR::ABL1, KMT2A::AFF1, ETV6::RUNX1

Received: 04 Jun 2025; Accepted: 07 Aug 2025.

Copyright: © 2025 Słota, Sędek, Lejman, Perkowski, Lasia, Bulsa, Mlynarski, Kowalczyk and Szczepański. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Łukasz Słota, Medical University of Silesia in Katowice, Department of Pediatric, Hematology and Oncology in Zabrze, Katowice, Poland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material